home / stock / kros / kros news

KROS News and Press, Keros Therapeutics Inc. From 05/25/21

Stock Information
Company Name: Keros Therapeutics Inc.
Stock Symbol: KROS
Market: NASDAQ
Website: kerostx.com
Menu
KROS KROS Quote KROS Short KROS News KROS Articles KROS Message Board
Get KROS Alerts

News, Short Squeeze, Breakout and More Instantly...
KROS - Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders

LEXINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscul...
KROS - Keros Therapeutics presents KER-012 preclinical data in pulmonary arterial hypertension in rodents

Keros Therapeutics (KROS) announces results from a preclinical study of KER-012 on pulmonary and cardiac dysfunction in an established rodent model of pulmonary arterial hypertension ((PAH)) at the virtual American Thoracic Society International Conference held May 14-19. KER-012 prevented ma...

KROS - Keros Therapeutics Presents Results from Preclinical Study of KER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

LEXINGTON, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferin...

KROS - Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscul...
KROS - Keros Therapeutics EPS misses by $0.10

Keros Therapeutics (KROS): Q1 GAAP EPS of -$0.68 misses by $0.10.Cash and cash equivalents of $255.2MPress Release For further details see: Keros Therapeutics EPS misses by $0.10

KROS - Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferin...

KROS - NAKD, MOTS, TWTR and MVIS among midday movers

Gainers: Brooklyn ImmunoTherapeutics (BTX) +58%.Regional Health Properties (RHE) +49%.Motus GI Holdings (MOTS) +31%.Bel Fuse (BELFB) +29%.Image Sensing Systems (ISNS) +23%.Farmmi (FAMI) +20%.CryoLife (CRY) +18%.Naked Brand (NAKD) +17%.Laureate Education (LAUR) +14%.Insignia Sys...
KROS - Brooklyn ImmunoTherapeutics, Motus GI leads healthcare gainers; Ardelyx, Pacific Biosciences of California among major losers

Gainers: Brooklyn ImmunoTherapeutics (BTX) +38%, Motus GI MOTS +32%, CryoLife (CRY) +16%, Mesoblast MESO +14%, Arcutis Biotherapeutics (ARQT) +10%.Losers: Ardelyx (ARDX) -13%, Pacific Biosciences of California (PACB) -13%, ALX Oncolo...

KROS - Keros Therapeutics EPS beats by $0.08

Keros Therapeutics (KROS): Q4 GAAP EPS of -$0.49 beats by $0.08.Cash and cash equivalents of $265.88M.Press Release For further details see: Keros Therapeutics EPS beats by $0.08

KROS - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

LEXINGTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffer...
Previous 10 Next 10